Timothy Bisson's Colleagues at QED Therapeutics
Sam Casillas
Head of KOL Advocacy Development, Oncology/Rare Disease Marketing & Commercialization
Timothy Bisson's Contact Details
HQ
650-231-4088
650-231-4088
Location
Company
QED Therapeutics
QED Therapeutics
Timothy Bisson's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Timothy Bisson
Timothy Bisson currently works for QED Therapeutics.
Timothy Bisson's role at QED Therapeutics is Senior Director- Market Access.
Timothy Bisson's email address is ***@qedtx.com. To view Timothy Bisson's full email address, please signup to ConnectPlex.
Timothy Bisson works in the Biotechnology industry.
Timothy Bisson's colleagues at QED Therapeutics are Quinn Nazarewycz, Jennifer Lai, Shivani Pandit, Chelsea Guiseppi, Sam Casillas, Deborah Mortensen, Yvonne Stone and others.
Timothy Bisson's phone number is 650-231-4088